Radiation Therapy
…advanced cases of melanoma where surgery is not possible or may be complicated. It is rarely used to treat primary melanoma. Exceptions include patients…
Radiation Therapy
…advanced cases of melanoma where surgery is not possible or may be complicated. It is rarely used to treat primary melanoma. Exceptions include patients…
Dealing With The Diagnosis
…with and manage a melanoma diagnosis. We have three general suggestions and several additional strategies on how to cope with…
UPMC Hillman Cancer Center | March 26, 2022
…MD 9:10 AM ET Nutrition for Melanoma Patients Darcy Ploucha, PA-C, MPAS Physician Assistant, Senior UPMC Hillman Cancer Center https://youtu.be/C5BY48bwS9s…
Caring For The Patient’s Self-Fulfilling Needs
…through the journey. In fact, some of the events that survivors choose to participate in, such as for-cause physical activities…
Saint John’s Cancer Institute | Oct. 29, 2022
…and Breakfast 8:45 AM PT Welcoming Remarks Rick Essner, M.D. FACS Surgical Director Melanoma Cancer Program Saint John’s Cancer Institute…
Stocks, IRA, and DAF Gifts
You can make a difference in melanoma research today. A gift of publicly traded stock can be a win-win for…
Roswell Park Comprehensive Cancer Center | April 20, 2024
…ET Strategies for Screening and Prevention of Melanoma Mary Reid, MSPH, PhD Professor of Oncology Chief, Cancer Screening and Survivorship…
Providence Cancer Institute of Oregon | Friday, Oct. 25, 2024
…MelanomaMucosal MelanomaOcular MelanomaPediatric MelanomaI Prefer not to Respond Stage of Melanoma Stage (in situ)Stage IStage IIStage IIIStage IVN/APrefer not to…
Suggested Reading
Melanoma: Not Just Skin Cancer BY CATHERINE M. POOLE WITH CONTRIBUTING EDITORS: JEDD WOLCHOK, MD AND KEITH FLAHERTY, MD Her new…
Skin Lesions That May Become Melanoma
…cause health problems, but a small percentage may develop into melanoma later in life. The risk of melanoma increases with…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026